(3.238.186.43) 您好!臺灣時間:2021/03/02 10:42
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:洪啟庭
研究生(外文):Ci-Ting Hong
論文名稱:決明子對青光眼小鼠降眼壓功能之研究
論文名稱(外文):The Intraocular Pressure-Lowing Activity of Semen Cassia in DBA/2J Mice Glaucoma Model
指導教授:陳福安陳福安引用關係
指導教授(外文):Fu-an Chen
學位類別:碩士
校院名稱:大仁科技大學
系所名稱:製藥科技研究所
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2011
畢業學年度:100
語文別:中文
論文頁數:144
中文關鍵詞:決明子青光眼遺傳性青光眼小鼠
外文關鍵詞:Semen CassiaGlaucomaDBA/2J mice
相關次數:
  • 被引用被引用:0
  • 點閱點閱:5314
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
青光眼是造成人類失明的主要原因之ㄧ,而其視力的喪失最主要是眼壓的升高造成機械性的壓迫,使得視網膜神經節死亡與視神經萎縮,進而造成青光眼患者視力的喪失。決明子是中國傳統醫學上用來治療青盲的重要中藥,本實驗則比較決明子與現代醫學中兩種降眼壓藥物其彼此的抗氧化能力、降眼壓效果及治療後的併發症等。
方法:選取10隻正常小鼠(C57BL/6J)與26隻遺傳性青光眼小鼠(BDA/2J),平均年齡約為3個月,依不同的治療方式分為六組(控制組、點眼藥brimonidine組、口服acetazolamide組、低中高劑量決明子萃取物組),在進行治療前與治療後五週測其房水中的LDH值、眼壓升降、紀錄體重變化、眼睛與肝腎的組織切片檢查。
結果︰結果一︰接受治療後五週,其代表抗氧化壓力下受損程度的LDH值,在brimonidine、口服中高劑量決明子萃取物等組別,均有明顯降低。結果二:以brimonidine、acetazolamide治療、口服低、中高劑量決明子萃取物等組別,其第五週後眼壓均出現明顯降低。結果三:口服acetazolamide組的青光眼小鼠其體重明顯降低,而其組織病理檢查則發現肝臟有局部的肝細胞凋亡與淋巴球浸潤、腎臟的腎小管則有局部萎縮與發炎細胞浸潤。結果四:點眼藥brimonidine組的青光眼小鼠其角膜出現白斑,而在組織切片下發現鮑氏囊層有沉積物及基質層的囊狀退化情形。
結論︰由本實驗發現口服低、中、高劑量的決明子萃取物其降眼壓效果(五週後)與增強房水液中抗氧化的能力,與點眼用藥brimonidine和口服用藥acetazolamide 相比較,並無明顯差異。此外服用決明子萃取物的小鼠,其肝臟、腎臟與眼睛的病理組織切片並無明顯異常;且外觀與生長狀況亦稱良好。以上結果推論決明子確有治療青盲上的理論基礎,在臨床上應可用來治療與預防人類的青光眼。
Background:
Glaucoma is mainly cause of blindness in the world. Visual loss in glaucoma typically involves retinal ganglion cell death and optic nerve atrophy subsequent to a pathologic elevation of intraocular pressure(IOP). The Semen Cassia (Jue Ming Zi) were used to cure glaucoma in ancient China. In this study, we evaluate the potential of Cassia tora in the treatment of glaucoma.
Method:
Young (mean ages:3 months) inherited glaucoma mice (BDA/2J; n=26) and health mice (C57BL/6J; n=10) were enrolled in this study. To
evaluate the potential of Semen Cassia the treatment of glaucoma,, all animals were divided into six groups. There were one shame group, two groups of control(topical brimonidine instillation and oral acetazolamide), and three groups treated by semen cassiae extract (low, middle and high doses). The anti-glaucoma effect of Semen Cassia was access by LDH and IOP. The side effect was investigated, too.
Results:
In result 1: LDH level was significantly lower than the baseline with the treatment of brimonide, middle and high doses of Semen Cassia. In result 2: the IOP was also lower than the pre-treatment level with the treatment of two lowering IOP drugs and any doses of Semen Cassia. In result 3: abnormal weight gain occurred after approximately five weeks with taking oral acetazolamide. In result 4: we found renal tubular focal atrophy and mild hepatocyte aptosis combined with inflammatory cells in the oral acetazolamide group. Besides, corneal opacity was found in topical brimonide instillation group, and the results of pathology showed subepithelial deposits and cystic degeneration within stromal layer.
Conclusion:
The ability to lower IOP and the activity of antioxidants in the middle and high doses of Jue Min Zi were equal to the groups of brimonide and acetazolamide used. The Semen Cassia is a relatively safe Chinese herbal medicine because no side effect was observed such as body weight loss, pathologic change. Perhaps, combination of the extracts of Semen Cassia with other anti-glaucoma drugs in treating the development and progression of glaucoma in the future could be expected.
目錄
中文摘要…………………………………………………………… Ⅰ
英文摘要…………………………………………………………… Ⅲ
誌謝………………………………………………………………… Ⅴ
目錄………………………………………………………………… Ⅵ
表目錄……………………………………………………………… Ⅶ
圖目錄……………………………………………………………… Ⅷ
第一章 前言……………………………………………………… 1
第二章 文獻回顧………………………………………………… 5
第三章 材料與方法……………………………………………… 9
第四章 結果……………………………………………………… 19
第五章 討論……………………………………………………… 26
第六章 結論……………………………………………………… 71
參考文獻……………………………………………………………108
Quigley HA. Number of people with glaucoma worldwide. Br J Opthalmol 1996; 80(5):389-93.
Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989; 107: 186-8.
Kass MA., Heuer DK., Higginobotham EJ., Johnson CA., Keltner CA,, Mililler JP., Parrish RK 2nd., Wilson MR., Gordon HO. The ocular Hypertension Treatment Study: a random trial determines that topical ocular hypertensive medication delayeds or prevents the onset of primary opne-angle glaucoma. Arch Ophthalmol. 2002; 120(6): 701-13.
Stewart WC., Kolker AE., Sharp ED., Day DG., Holmes KT., Leech JN., Johnson M., Cantrell JB. Factors associated with long-term progression or stability in primary open-angle. Am J Ophthalmol 2000; 130(3): 247-9.
Sommer A., Tielsch JM. Risk factors for open-angle glaucoma. Arch Ophthalmol 1996; 114(2): 235.
Sommer A. Collabrative normal-tension glaucoma study. Am J Ophthalmol 1999; 128(6): 776-7.
Chen JZ., Kadlubar FF. A new clue to glaucoma pathogenesis. Am. J. Med. 2003; 114:697-8.
Fingeret M. Glaucoma medications. Glaucoma therapy and the evolving paradigm. J Am Optom Assoc. 1998; 69(2): 115-21.
Levy Z., Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr(Phila) 2004; 43(1): 99-101.
Lam W., Bussom S., Guan F., Jiang Z., Zhang W., Gullen EA., Liu SH., Cheng YC. The four herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010; 2(45): 45-59.
Li Y., Xu C., Zhang Q., Liu JY., Tan RX. In vitro anti-Heliobacter pylori action of 30 Chinses herbal medications used to treat ulcer diseases. J Ethnopharmacol 2005; 98(3): 329-33.
Liu X., Hu Z., Shi Q., Zeng H., Shen Y., Jin H., Zhang W. Anti-inflammatory and anti-nociceptive activities of compounds from Tinospora sagittata(Oliv.) Gagnep. Arch Pharm Res 2010; 33(7): 981-7.
Li PC., Lam E., Roos WP., Zdzienicka MZ., Kaina B., Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008; 68: 4347-51.
Mar PG., Read BE. Chemical examination of chinese remedies for nightbliness. Chin J Physiol 1936; 10(2): 273.
Namba T, Yaku W. Hoikusha publishing Co Ltd 1980; Vol: 226.
Wong SM., Wong M, Seligmann O, Wagner H. N. New antihepatotoxic naphtho-pyrone Glycoside from the seeds of Cassia tora. Planta Med 1989; 55(3):276-80.
Kim DH., Kim S., Jung WY., Reidel G., Kim DH., Ryu JH., Chio DY., Platt B. The seeds extract of Cassia obtusiofolia on transient cerebral ischemia in mice. Food Chem Toxicol 2009; 47(7):1473-9.
Sung BK., Kim MK., Lee WH., Lee DH., Lee HS. Growth responses of Cassia obtusifolia toward human intestinal bacteria. Fitoterpia 2004; 75: 505-9.
Cho IJ., Lee C., Ha TY. Hypolipidemic effects of soluble fiber isolated from seeds of Cassia tora Linn. in rats fed a high-cholesterol diet. J Argric Food Chem. 2007; 55: 1592-6.
Choi HS., Kim JH., Takido M. Potential inhibitors of platelet aggregation form plant sources, V. Anthraquinones from seeds of Cassia obtusifolia and related compounds. J Nat Prod 1990; 53(3):630- 3.
El-halawany AM., ChungMH., Nakamura N., Ma CM., Nishihara T., Hattori M. Estrogenic and anti-estrogenic activities of Cassia tora phenolic constituents. Chem Pharm Bull(Tokyo) 2007; 55(10): 1476-82.
Nikaido T, Ohmoto T, Sankawa U, Kitanaka S, Takido M. Inhibitors of adenosine 3’, 5’ – cyclic monophosphate phosphodiesterase in Cassiaseeds. Chem Pharm Bull(Tokyo) 1984; 32(8): 3075-8.
Cao A., Sha M., Meng S., Jiang L., Zhang Z. Determination of chrysophanol in semen Cassiae by HPLC. Zhongguo Zhong Yao Zhi. 1997; 22(2): 107-8.
Wen KC. Years of Chinese Medicine and Pharmacy. 2008; 26(4): 81-126.
Bais R., Philcox M. Approved recommendation on IFCC methods for the measurement of catalytic concentration of enzymes. Part 8. IFCC Method for Lactate Dehydrogenase (1-Lactate: NAD + Oxidoreductase, EC 1.1.1.27). International Federation of Clinical Chemistry (IFCC). Eur J Clin Chem Clin Biochem 1994; 32(8): 639-55.
Zegar SL., Liang KY. Longitudinal data analysis for discreste and continuous outcomes. Biomettric 1986; 41(1): 121-30.
Zhu YP. Chinese materia medica chemistry, pharmacology and Application. The Netherlands; Hawood Academic Publishers; 1998: 9: 1124-5.
Sakanaka K., Kawazu K., Tomonari M., Kitahara T., Nakashima M., Nishida K., Nakamura J., Sasaki H., Higuchi S. Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs. Biol. Pharm. Bull(Tokyo). 2008; 31(8):1590-5.
Burke J., Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996; 41(supple 1):S9-18.
Mincione F., Scozzafava A., Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des 2008; 14(7): 649-54.
Portellos M., Burckley EG., Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatrec glaucoma. JAAPOS 1998;21(1):43-4.
Spencer NA, Hall AJ, Stawell RJ. Nd:YAG laser iridotomy in uveitic glaucoma. Clin Experiment Ophthalmol 2001; 29(4): 217-9.
Sun X., Liang YB., Wang NL., Fan SJ., Sun LP., Li SZ., Liu WR. Laser peripheral iridotomy with and without iridoplasty for primary angle-closure glaucoma: 1-year results of a randomized piolt study. Am J Ophthalmol 2010; 150(1):68-73.
Atanassov MA. Surgical treatment of glaucoma by trabeculectomy – indication and early results. Folia Med(Plovdic) 2009;51(4):25-8.
Kiuchi Y., Tsujino C., Nakamura T., Otori Y., Mochizuki H. Phacoemulsification and trabeculotomy combined with goniosynchialysis for untrollable chronic angle-closure glaucoma. Ophthalmic Surg Lasers imaging 2010; 41(3):348-54.
Mosaed S., Dustin L., Minckler DS. Comparative outcomes between newer and older surgeries for glaucoma. Trans Am Ophthalmol Soc 2009; 107: 127-33.
McDonnad TO., Hodges JW., Borgmann AR., Lenders FE. The water-loading test in rabbits; a method to detect potential ocular hypotensive drugs. Arch Ophthalmol 1969; 82:381- 4.
Himber K., De Burlet G., Andermann G. Effects of adrenergic agents on alpha-chymotrypsin-induced ocular hypertension in albino and pigmented rabbits: a comparative study. J Ocular Pharm 1989; 5:93-8.
Gelatt KN., Brooks DE., Samuelson DA. Comparative glaucomatology. II: The experimental glaucomas. J Glaucoma 1998; 7(4): 282-94.
Galassi F., Masini E., Giambene B., Fabrizi F., Uliva C., Bolla M., Ongini E. A typical nitric oxide-releasing dexamehtasone derivates : effects of intraocular pressure and ocular haemodynamics in a rabbit glaucoma model. Br J Ophthalmol 2006; 90(11):1414-9.
Agarwal R., Gupta SK., Srivastava S., Saxena R., Agrawal SS. Intraocular pressure-lowering activity of topical application of Aegle Marmelos fruit extract in experimental animal models. Ophthalmic Res 2009; 42(2): 112-6.
Wolde-Mussie E., Ruiz G., Wijono M., Wheeler LA. Neuroprotection of retinal ganglion cells by Brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42(12): 2849-55.
Levkovitch-Verbin H., Quigley HA, Martin KRG, Valenta D, Baumrind LA, Pease ME. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rates. Invest Ophthalmol Vis Sci 2002; 43(2): 402-10.
John SW., Smith RS., Savinova OV., Hawes CL., Chang B., Turnbull D., Davisson M., Roderick TH., Heckenlively JR. Essential iris atrophy, pigment dispersion and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci 1998 ; 39(6):951-62.
Libby RT., Gould DB., Anderson MG., John SW. Complex genetics of glaucoma susceptibility. Annu Rev Genomics Hum Genet. 2005; 6: 15- 44.
Anderson MG., Smith RS., Hawes TH., Heckenlively JR., Davission MT., John SW. Mutations in genes encoding melanosomal proteins cause pigment glaucoma in BDA/2J mice. Nat Genet 2002; 30:81-5.
Chang B., Smith RS., Hawes NL., Anderson MG., Zabaleta A., Savinova O., Roderick TH., Heckenlively JR., Davisson MT., John SW. Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice. Nat Genet 1999; 21(4):405-9.
Mo JS., Anderson MG., Gregory M., Smith RS., Savinova OV., Serreze DV., Ksander BR., Streilein JW., John SW. By altering ocular immune privilege, bone marrrow-derived cells pathogeneically contribute to DBA/2J pigmentary glaucoma. J Exp med. 2003; 19: 197(10): 1335-44.
Danias J., Lee KC., Zamora MF., Chen B., Shen F., Filippopoulos T., Su Y., Foldblum D., Podos SM., Mittag T. Qunatitative analysis of retinal ganglion cell (RGC) loss in aging DBA/2N Nia glaucomatous mice comparison with RGC loss in aging C57/BL6 mice. Invest Ophthalmol Vis Sci 2003; 44: 5151-62.
Anderson MG., Smith RS., Hawes NL., Zabaleta A., Chang B., Whipan R., Heckenlively JR., Davisson M., John SW. Genetic modification of glaucoma associated phentypes between AKXD-28 /Ty and DBA/2J mice. BMC Genetics 2001;2:1.
John SW. Mechanism insight to glaucoma provided by experimental genetics: The Cogan lecture. Invest Ophthalmol Vis Sci 2005;46:2649-61.
Zhou X., Li F., Kong L., Tomita H., Li C., Cao W. Involvement of inflammation, degradation and apoptosis in a mouse model of glaucoma. J Biol Chem 2005; 280(35):31240-8.
Schuettauf F., Quinto K., Naskar R., Zurakowski D. Effects of anti-glaucoma medications on ganglion cell survial: the DBA/2J mouse model. Vision Res 2002; 42(20): 2333-7.
Fan W., Li X., Wang W., Mo JS., Kaplan H., Copper NG.. Early involvement of immune/inflammatory response genes in retinal degeneration in DBA/2J mice. Ophthalmol Eye Dis. 2010; 1: 23- 41.
Libby RT., Anderson MG., Pang IH., Robinson ZH., Savinova O., Cosma IM., Snow A., Wilson LA., Smith RS., Clark AF. Inherited glaucoma in DBA/2J mice: pertinent disease features for studying the neurodegeneration. Vis Neurosci 2005; 22:637- 48.
Savinova OV., Sugiyama F., Martin JE., Tomarev SI., Paigen BJ., Smith RS., John SW. Intraocular pressure in genetically distinct mice: An update and strain survey. BMC Genet 2001; 2:12.
Bhattacharya SK., Peachey NS., Crabb JW. Cochin and glaucoma: A mini-review. Vis Neurosci 2005; 22(5): 605-13.
Inman DM., Sappington RM., Horner PJ., Calkins DJ. Quantitative correction of optic nerve pathology with ocular pressure and corneal thickness in the DBA/2 mouse model of glaucoma. Invest Ophthalmol Vis sci 2006; 47(3): 986-96.
Nakagami T., Yamazaki Y., Hayamizu F. Study on relationship between control of intraocular pressure and systemic risk factor for visual field progression in normal tension glaucoma. Nippon Ganka Gakkai Zasshi 2010; 114(7): 592-7.
Aoyama A., Ishida K., Sawada A., Yamamoto T. Target intraocular pressure for stability of visaul field loss progression in normal tension glaucoma. Jpn J Ophthalmol 2010; 54(2): 117-23.
Konareva-Kostianeva MI., Atanasov MA., Gerdzhikov A., Chilova-Atanasova BK. Distribution of glaucoma by type, stage of development and therapy. Folia Med(Plovdiv); 2009: 51(3): 37- 41.
Baltan S., Inman DM., Danilov GA., Morrison RS., Galkins DJ., Horner PJ. Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration. J Neurosci 2010; 30(16): 5644-52.
Craig JE., Mackey DA. Glaucoma genetics: where are we ? Where will we go ? Curr Opin Ophthalmol 1999; 10(2):126-34.
Sommer A., Tieisch J. Blood pressure, perfusion pressure and open-angle glaucoma. Arch Ophthalmol 2008; 126(5):741.
Anderson DR., Hendrickson A. Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve. Invest Ophthamol Vis Sci 1974; 13: 771-83.
Quigley HA., Nickells RW., Kerrigan LA., Pease ME,, Thibault DJ., Zack DJ. Retinal ganglion cell death in experimental monkey glaucoma and axotomy occurs by apoptosis. Invest Opthalmol Vis Sci 1995; 36(5): 774-86.
Flammer J., Haefliger IO., Orgul S., Resink T. Vascular dysregulation: a principal risk factor for glaucomatous damage ? Glaucoma, 1999:8(3): 212-9.
Vorwerk CK., Hyman BT., Miller JW., Husain D., Zurakowski D., Huang PL., Fishman MC., Dreyer EB. The role of neuronal and endothelial nitric oxide synthase in retinal excitotoxicity. Invest Ophthamol Vis Sci 1997; 38(10): 2038-44.
Ferreira SM., Lerner MS., Brunzini R., Evelson PA., Llesuy SF. Oxidative stress makers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004; 137(1):62-9.
Welge-Lüssen U., Brike K. Oxidative stress in the trabecular meshwork of POAG. Klin Monbl Augenheilkd. 2010; 227(2):99-107.
Yildrim Ö., Ates NA., Ercan B., Muslu N., Ünlü A., Tamer L., Kanik A. Role of oxidative stress in open-angle glaucoma. Eye 2005; 19(5): 580-3.
Alvarado J., Murphy C., Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 1984; 91(6): 564-79.
Halliwell B., Gutteridge JM., Cross CE. Free radicals, antioxidants, and human disease: where are we now ? J Lab Clin Med 1992; 119(6): 598-620.
Spector A., Garner WH. Hydrogen peroxide and human cataract. Exp Eye Res 1981; 33: 673.
Ames BN., Shigenaga MK., Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Pro Natl Acda Sci USA 1993; 90: 7915-22.
Heck DE., Shakarjian M., Kim HD., Lasikn JD., Vetrano AM. Mechanisms of oxidant generation by catalase. Ann NY Acad Sci 2010; 1203: 120-5.
Aruoma OI. Nutrition and health aspects of free radicals and antioxidants. Food Chem Toxicol 1994; 32(7): 671-83.
Chen FA., Wu AB., Shieh PC., Kuo DH., Hsieh CY. Evaluation of the antioxidant activity of Ruellia tuberosa. Food chemistry. 2006; 94: 14-8.
Rose RC., Richer SP., Bochem AM. Oocular antioxidants and antioxidant potection Proc. Exp. Biol. Med. 1988; 217:397-407.
Stephen B., Koh H., Phil M., Henson D., Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 1987; 71:766-71.
Żoriċ L. Parameters of oxidative stress in the lens, aqueous humor, and blood in patients with diabetes and senile cataracts. Spr Arch Celok Lek. 2006 131(3-4): 137- 42.
Izzotti A., Bagnis A., Saccà, S.C. The role of oxidative stress in glaucoma. Mutat Res 2006; 612(2): 105-14.
Green K. Free radicals and aging of anterior segment tissuees of th eye : a hypothesis. Ophthalmic Surg 1995; 27(supp1) 143-9.
Zhou L., Li Y., Yue, B.Y. Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: the trabecular meshwork. J cell Physiol. 1999; 180(2): 182-9.
Frish S.M., Ruoslahti, E. Integrins and anokis. Curr Cell Biol. 1997; 9: 701-6.
Nguyen KPV., Chung, ML., Anderson PJ., Johnson M, Epstein DL. Hydrogen peroxide removal by the calf aqueous outflow pathway. Invest Ophthalmol Vis Sci 1988;29:976-1.
Kahn M., Giblin F., Epstein D. Glutathione in calf trabecular meshwork and its relation to aqueous humor outflow facility, Invest Ophthalmol Vis Sci 1985; 26: 1330-5.
Richer SP., Rose RC. Water soluble antioxidants in mammalian aqueous humor︰Interaction with UV and hydrogen peroxide. Vis Res 1998; 38:2881-8.
Repetto M., Reides C., Carretero M., Costa M., Griemberg G., Llesuy S. Oxidative stress in blood of HIV infected patients. Clinica Chimica Acta 1996; 255:107-17.
Famulari A., Marshoff E., Lleusuy S., Llusuy SF., Kohan S., Serra S., Serra JA., Dominguez RO., Repetto M., Reides C., Sacerdote de Lustig E. The antioxidant enzymatic blood profile in Alzheimer’s and vascular disease: their association and a possible assay to differentiate demented subjects and controls. J Neuro Sci 1996; 141: 69-78.
Lores Arnaiz S., Travacio M., Monserrat A., Cutrin J., Lleusuy S, Boveris A. Chemiluminescene and antioxidant levels during peroxisome proliferation by fenofibrate. Biochim Biophys Acta 1997; 1360: 222-8.
Kurysheva NI., Vinetskaia MI., Erichev VP., Artamonov VP., Uspenskaia AP. Contribution of free-radial reactions of chamber to the development of primary open-angle glaucoma(in Russian). Vestn Oftalmol 1996; 112: 3-5.
Babizhayev MA., Brodskaya MW. Fibronectin detection in drainage outflow system of humor eyes in aging and progression of open-angle glaucoma. Mech Ageing Dev 1989; 47: 145-57.
Keller JN., Mattson MP. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev Neurosci 1998; 9(2) 105-16.
Kourie JI. Interaction of reactive oxygen species with ion transport mechanism. Am J Physiol. 1998; 275(1Pt1): C1-24.
Vendemiale G., Grattagliano I., Altomare E. An update on the role of free radicals and antioxidant defense in human disease. Int J Clin Lab Res 1999; 29(2):49-55.
Stone RA., Krupin T. Elevated lactic acid dehydrogenase in aqueous humor in an eye without retinoblastoma. Am J Ophthalmol 1976; 82: 94-6.
Kaneko A, Suzuki H. Lactic acid dehydrogenase activity and isoenzyme in retinoblastoma. Acta Soc Opthalmol Jap 1972 ; 76:672.
Jakobiec FA., Abramson D., Scher R. Increased aqueous lactate dehydrogenase in Coat’s disease. Am J Ophthalmol. 1978; 85(5 Pt 1): 686-9.
Chayakul V., Reim. The enzymatic activities in the alkali-burnt rabbit Cornea. Graefes Arch Clin Exp. 1982; 218(3): 145-8.
Takahashi H., Fujimoto C., Matsui H., Igarashi T., Shiwa T., Ohara K., Sugita T. Anterior chamber ittigation with an ozonated solution as prophylaxis against infectious endophthalmitis. J Cataract Refract Surg. 2004; 30(8): 1773-80
Swartz M, Herbst WR, Goldberg FM. Aqueous humor lactic acid dehydrogenase in retinoblastoma. Am J Ophthalmol 1974; 78:612.
Kabak J, Romano EP. Aqueous humor lactic acid dehydrogenase isoenzyme in retinoblastoma. Br J Opthalmol 1975; 59:268.
Berman ER. Biochemistry of the eye. New York : Plenum Press: 1991.
Nagpal RC., Singh RC., Singh G., Ahluwalia BK. Total lactate dehydrogenase and its isoenzyme pattern in lens, aqueous humor, and serum in cases of senile cataract. Acta Ophthalmol 1991; 69: 57-60.
Jovanovic P., Zoric L., Stefanovic I., Dzunic B., Djordjevic-Jocic J., Radenkovic M., Jovanovic M. Lactate dehydrogenase and oxidative stress activity in primary open-angle glaucoma aqueous humour. Bosn J Basic Med Sci. 2010 ;10(1): 83-8.
Li W., Yin X., Zhang C., Li L, Wang L., Xiao Y. Comparative study between Cassia obtusifolia and processed Cassia obtusifolia on anti-oxidation effect and NO/ET secretion. Zhongguo Zhong Yao Za Zhi 2009; 34(18): 2383-5.
Lee KY., Nakayama M., Aihara M., Chen YN., Araie M. Brimonide is neuroprotective against glutamate-induced neurotoxicity, oxidative stress and hypoxia in purified rat retinal ganglion cells. Mol Vis 2010; 16:246-51.
Yu ZK., Chen YN., Aihara M., Mao W. Uchida S, Araie M. Effects of beta-adrendergic receptor antagonists on oxidative stress in purified rat retinal ganglion cells. Mol Vis 2007; 13: 833- 9.
Nowrrozzadeh MH., Razeghinejad MR. Brimonidine and eye pressure. Ophthalmology. 2010; 117(7):1463.
Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brinomide on aqueous humor dynamics in human eyes. Arch ophthalmol 1995; 113(12): 1514-7.
Rahman MQ., Ramaesh K., Montgomery DM. Brimonide for glaucoma. Expert Opion Drug Saf. 2010; 9(3): 483-91.
Becker B. Decrease in intraocular pressure in man by carbonic anhydrase inhibitors, Diamox. Am J Ophthalmol 1954; 37: 13.
Lichter PR., Musch DC., Medzihradsky F., Standardi CL. Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma. Am J Ophthalmol. 1989; 107(1):11-7.
Maus TL., Larsson L., McLaren JW., Brubaker RF. Comparision of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997; 115: 45-9.
Hitchings R. Traumatic glaucoma. J Glaucoma. 2001; 10(5): 436-9.
Agarwal R., Gupta SK., Srivastava S., Agrawal SS., Saxena R. Lowering of intraocular pressure by topical application of Daucus carota seed extract in rabbits. Indian J Exp Boil. 2008; 46: 541-6.
Chan SHH., Koo A., Li KM. The involvement of medullary reticular formation in the hypotensive effect of extracts from seeds of Cassia Tora. Amer J Chin Med 1976; 4(3): 383-9.
Koo A., Wang CC., Li, KM. Extraction of hypotensive principles from seeds of cassia tora. Amer J Chin Med 1976; 4(3): 245-8.
Huang HC., Lee CR., Chao PD., Chen CC., Chu SH. Vasorelaxant effect of emodin, an anthraquinone from a Chinese herb. Eur J Pharmacol 1991;205(3):289-94.
Caprioli J., Coleman AL. Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol 2010; 149(5): 704-12.
Memarzadeh F., Ying-Lai M., Churn J., Azen SP., Varma R. Blood pressure, perfusion, and open-angle glaucoma: the Los Angles Latino Eye Study. Invest Ophthalmol Vis Sci 2010; 51(6): 2872-7.
Torring MS., Holmgarrd K., Hessellund A., Aakjaer C., Bek T. The vasodilating effect of acetazolamide and dorzolamide involoves mechanisms other than carbonic anhydrase inhibiton. Invest Ophthalmol Vis Sci 2009; 50(1):345-51.
Macdonald MJ., Gore SM., Cullen PM. Phillips CI. Comparision of ocular hypotension effects of acetazolamide and atenolol. Br J Ophthalmol 1977; 61(5): 345-8.
Gilani AH., Shaheen E., Saeed SA., Bibi S., Irfanullah., Sadiq M., Faizi S. Hypotensive action of coumarin glycosides from Daucus carota. Phytomedicine. 2000; 7(5): 423-6.
Agarwal R., Gupta SK., Srivastava S., Agrawal SS., Saxena R. Lowering of Intraocular pressure by topical application of Daucus carota seed extract in rabbits. Indian J Exp Biol 2008; 46(7): 541-6.
Sharma RS., Asrani D. Aegle marmelos(BEL) leaf extract (extractum belae fruit liquim) in the management of hypertension. J Assoc Physicians India. 2003; 51: 1252.
Campbell DA. Diuretics and the eye. Br Med J. 1961; 2: 467-74.
Roy LF., Dufresne LR., Legault L., Long H., Moric C. Acetazolamide in hemodialysis patients: a rational use after ocular surgery. Am J Kidney Dis. 1992; 20(6):650-2.
Portellos M., Buckley EG., Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. J AAPOS 1998; 2(1): 43-7.
Whelton A., Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kideny function. J Cli Pharmacol 1991; 31: 588-98.
Gasparotto A Jr., Boffo MA., Lourenco EL., Stefanello ME., Kassuya CA., Marques MC. Natriuretic and diuretic effects of Topaeolum majus (Tropaeolaceae) in rats. J Ethnopharmacol 2009; 122(3): 517-22.
Klimas R., Rabiskovi M., Civinskiene G., Bernatoniene J. The diuretic effect of cornflower water extract. Medicina(Kaunas) 2007; 43(3): 221-5.
Bogolepova AE., Shakhmatova EI. Role of prostaglandin E2 in regulation of urine excretion in saluresis, water and osmatic diuresis in rats. Ross Fiziol Zh Im I M Sechenova. 2004; 90(11): 1411-6.
Nikaido T., Ohmoto T., Sankawa U., Kitanka S., Takido M. Inhibitors of Adenosine 3’,5’-cyclic Monophosphate Phosphodiesterase in cassia seed. Chem Pharm Bull(Tokyo) 1984; 32(8): 3075-8.
Rosenberg LF., Krupin T., Hong PH., Ruderman JM. Combinaton of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology 1998; 105:88-95.
Epstein DL., Grant WM. Carbonic anhydrase inhibitors side effects. Arch ophthalmol 1977; 95:1378-82.
Maisey DN., Brown RD. Acetazolamide and symptomatic metabolic acidosis in mild renal failure. Br Med J 1981; 283: 1527-8.
Brown AS. Renal tubular acidosis. Dimens Crit Care Nurs 2010; 29(3): 112-9.
Chapron DJ., Gomolin IH., Sweeney KR. Acetazolamine blood concentrations are excessive in the elderly: propensity for acidosis and relationship ot renal function. J Clin Pharmacol 1989; 29:248-353.
Sharan S., Dupuis A., Hébert D., Levin AV. The effect of oral acetazolamide on weight gain in children. Can J Ophthalmol 2010;45(1):41-5.
Parikh JR., Nolan RL. Acetazolamide-induced nephrocalcinosis. Abdom Imaging 1994; 19(5):466-7.
Shield MB., Simmons RJ. Urinary calculus during methazolamide therapy. Am J Ophthalmol 1976; 81(5): 622-4.
Myonihan JB. Carbonic anhydrase activity in mammaliam skeletal and cardiac muscle. Biochem J 1977; 168; 567-9.
Ikeda K., Iwasaki Y., Kinoshita M., Yabuki D., Igarashi O., Ichikawa Y., Satoyoshi E. Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. Intern Med 2002; 41(9): 743-5.
Garske LA., Brown MG., Morrision SC. Acetazolamide reduces exercise capacity and increases leg fatigue under hypoxic conditions. J Appl Physiol 2003; 94(3): 991-6.
Herreras JM., Pastor JC., Calonge MC., Asensio VM. Ocular surface alteration after long term treatment with an anti-glaucoma drugs. Ophthalmology. 1992; 1082-8.
Sherwood MB., Grierson I., Millar L., hitchings RA. Long term morphologic effects of anti-glaucoma drugs on the conjunctiva and tenon’s capsule in glaucomatous patients. Ophthalmology 1989 ; 96: 327-35.
Yalvac IS., Gedikoğlu G., Karagöz Y., Akgün U., Nurözler A., Koç F., Kasım R., Duman S. Effects of antiglaucoma drugs on coular surface. Acta Ophthalmol Scand. 1995; 73(3): 246-8.
Rahman MQ., Ramaesh K., Montgomery DM. Brimonidine for glaucoma. Expert Opin Drug Saf. 2010. 9(3): 483-91.
Katz LJ. Brimonide tartrate 0.2% twice daily vs 0.5% twice daily: 1 year results in glaucoma patietns. Brimonidine study group. Am J Ophthalmol 1999; 127(1): 20-6.
Schuman JS., Horwitz B., Choplin NT., David R., Albracht D., Chen K. A 1-year study of brimonide twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic brimonidine study group. Arch Ophthalmol 1997; 115(7): 847-52.
Edwards JD., Burka JM., Bower KS., Stutzman RD., Sediq DA., Rabin JC. Effect of brimonidine tartrate 0.15% on night-vision difficulty and contrast testing after refractive suegery. J Cataract Refract Surg 2008; 34(9): 1538-41.
Goold LA., Warrier SK., Wittles NK., Nathan F. Microbial keratitis secondary to infection with Citrobacter koseri. Cornea. 2010: 29(4): 479.
Baudouin C., Labbé A., Liang H., Pauly A., Brignole-Baudouin F. preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29(4): 321-34.
Minckler DS., Baerveldt G., Heuer DK., Quillen-Thomas B., Walonker AF., Weiner J. Clinical evaluation of the oculab Tono-Pen. Am J Ophthalmol. 1987; 104(2): 168- 73.
Dalke C., Pleyer U., Graw J. On the use of Tono-Pen XL for the measurement of intraocular pressure in mice. Exp Eye Res. 2005; 80(2): 295-6.
Bordon AF., Katsumi O., Hirose T. Tonometry in pediatric patients: a comparative study among Tono-pen, Perkins, and schiötz tonometers. J pediatr Ophthalmol Strabismus. 1995; 32(6): 373-7.
Filous A., Burdová M., Malec J. The Tono-pen XL – a tonometer suitable for measurement of common and less common conditions associated with intraocular pressure. Cesk Slov Oftalmol 1998; 54(3): 159-65.
Levy Y., Zadok D., Glovinsky Y., Krakowski D., Nemet P. Tono-Pen versus Goldmann tonometry after excimer laser photorefractive keractomy. J Cataract Refract Sur. 1999; 25(12): 1558- 60.
Goldblum D., Kontiola AL., Mittag T., Chen B., Danias J. Non-invasive determination of intraocular pressure in the rat eye: comparision of an electronic tonometer (TonoPen) and a rebound (impact probe) tonometer. Grafes Arch Clin Exp Ophthalmol 2002; 240: 942-6.
Rietsamer HA., Keil JW., Harrison JM., Ransom NL., McKinnon SJ. Tonopen measurement of intraocular pressure in mice. Exp Eye Res 2004; 78(4): 799-804.
Wolfs RC., Klaver CC., Vingerling JR., Grobbee DE., Hofman A., de Jong PT. Distribution of central corneal thickness and its associated with intraocular pressure : The Rotterdam Study. Am J Ophthalmol 1997; 123: 767- 72.
Shah S., Chatteriee A., Mathai M., Kelly SP., Kwartz J., Henson D., McLeod D. Relationship between corneal thickness and measured intraocular pressure in a general ophthalmology clinic. Ophthalmology. 1999; 106(11): 2154-60.
Foster PJ, Wong JS, Wong E, Chen FG, Machin D, Chew PT. Accurary of clinical estimate of intraocular prssure in Chinese eyes. Ophthalmology 2000; 107(10): 1816-21.
Yagi K. Lipid peroxides and human diseases. Chem Phys Lipids. 1987; 45(2-4): 337-51.
Osawa T., Katsuzaki H., Hagiwara Y., hagiwara H., Shibamoto T. Novel antioxidant isolated from young green barley leaves. J Agric Food Chem 1992; 42(7): 1135-8.
Wu JW., Lee HY., Ho CT., Chang SS. Elucidation of the chemical structure of nature antioxidants isolated from resemary. J Am Oil Chem Soc 1982; 59: 339-45.
Yen GC., Chen HY. Antioxidants activity of various tea extracts in relation to the antimutagenicity. J Argic Food Chem 1995; 43: 27-32.
Nishina A., Kubota K., Kameoka H., Osawa T. Antioxidizing component, Musizin, in Rumex japonicus Houtt. JAOCS 1991; 68(10): 735-9.
Choi JS., Lee JH., Park HJ., Kim HG., Young HS., Mun SI. Screening for antioxidant activity of plants and marine algae and its active principles from Prunus davidiana. Kor J Pharmacogn. 1993; 24(4): 299-303.
Malterud KE., Farbrot TL., Huse AE., Sund RB. Antioxidant and radical scavenging effects of anthraquinones and anthrones. Pharmacology 1993; 47(supple 1): 77-85.
Huang KC. Antihpercholeseterolemic herbs.In the pharmacology of Chinese herbs. CRC press : Boca Rotan, FL: 1993:103.
Choi JS., Lee HJ., Kang SS. Alaternin, cassiaside and rubrofusarin gentiobioside, radial scavenging principles from the seeds of Cassis tora on 1,1-diphenyl-2-picrylhydrazyl(DPPH) radial. Arch Pharm Res 1994; 17(6):462-6.
Yen GC., Chen HW., Duh PD. Extraction and identification of an antioxidative component from Jue Ming Zi(Cassia tora L.) J Agri Food Chem 1998; 46: 820-4.
Huang HC., Chang JH., Tung SF., Tung SF, Wu RT., Foegh ML. Immunosppressive effect of emodin, a free radical generator. Eur J Pharmacol 1992 ; 211: 359- 64.
Zhang Q., Zhou Z., Yin J., Wang Y., Sun J. Influence of temperature on chemical constituents and pharmacological effects of semen cassiae. Zhongguo Zhong Uao Za Zhi 1996; 21(11): 663-5.
Li W., Yin X., Zhang C., Li L., Wang L., Xiao YQ. Comparative study between Cassia obtusifolia and processed Cassia obtusifolia on anti-oxidation effect and NO/ET secretion. Zhongguo Zhong Yao Za Zi. 2009; 34(18): 2383-5.
Jan DS., Lee GY., Kim YM., Lee YM., Yoo JL., Kim JS. Anthraquinones from the seeds of Cassia tora with inhibitory activity on protein glycation and aldose reductase. Biol Pharm Bull. 2007; 30(11): 2207-10.
Guo H., Chang Z., Yang R., Guo O., Zeng J. Anthraquinones from hair roots cultures of cassia obtusifolia. Phytochemistry 1998, 49: 1623-6. 171.Kitanaka S,, Takido M. Studies on the constituents in the roots of Cassia obtusifolia L. and the antimicrobial activities of constituents of the roots and the seeds. Yakugaku Zhashi 1986; 106(4): 302-6.
Hatano T., Uebayashi H., Ito H., Shiota S., Tsuchiya T., Yoshida T. Phenolic constiuents of Cassia seeds and antibacterail effect of some naphthalenes and anthraquinones on methicillin-resistant staphylococcus aureus. Chem Pharm Bull (Tokyo) 1999; 47(8): 1121-7.
Kitanaka S., Nakayama T., Shibano E., Ohkosi E., Takido M. Antiallergic agent from nature sources. Structures and inhibitory effects of histamine release of naphthopyrone glycosides from seeds of Cassia obtusifolia. Chem Pharm Bull(Tokyo). 1998; 46(10): 1650-2.
Drever BD., Anderson WG., Reidel G., Kim DH., Ryu JH., Chio DY., Platt B. The seed extract of Cassia obtusiofolia offers neuroprotection to mouse hippocampal culture. J Pharmacol Sci; 2008: 107(4): 380-2.
Sheppard AL., Davies LN. In vivo analysis of ciliry muscle morphologic changes with accommodation and axial ametropia. Invest Ophthalmol Vis Sci. 2010; 51(12): 6882- 9.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔